• 1. Fate of single walled carbon nanotubes in wetland ecosystems?
  Joseph H. Bisesi,Tara Sabo-Attwood Environ. Sci.: Nano, 2014,1, 574-583
• 2. Fatty acid eutectic mixtures and derivatives from non-edible animal fat as phase change materials?
  Pau Gallart-Sirvent,Marc Martín,Gemma Villorbina,Mercè Balcells,Aran Solé,Luisa F. Cabeza,Ramon Canela-Garayoa RSC Adv., 2017,7, 24133-24139
• 3. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527
• 4. Establishing plasmon contribution to chemical reactions: alkoxyamines as a thermal probe?
  Olga Guselnikova,Gérard Audran,Jean-Patrick Joly,Andrii Trelin,Evgeny V. Tretyakov,Vaclav Svorcik,Oleksiy Lyutakov,Sylvain R. A. Marque Chem. Sci., 2021,12, 4154-4161
• 5. Dissociative electron attachment to HGaF4 Lewis–Br?nsted superacid
  Marcin Czapla,Jack Simons Phys. Chem. Chem. Phys., 2018,20, 21739-21745

3-Chloroquinuclidine Hydrochloride (CAS No. 33601-77-3): A Comprehensive Overview

3-Chloroquinuclidine hydrochloride (CAS No. 33601-77-3) is a significant compound in the field of medicinal chemistry and pharmaceutical research. This compound, also known as 3-chloroquinuclidine monohydrochloride, is a derivative of quinuclidine, a bicyclic organic compound with a unique structure that confers it with a range of biological activities. The 3-chloroquinuclidine hydrochloride salt form is particularly important due to its enhanced solubility and stability, making it a valuable candidate for various applications in drug development and chemical synthesis.

The quinuclidine core structure is characterized by a seven-membered nitrogen-containing ring fused to a six-membered ring, which provides it with unique chemical and pharmacological properties. The introduction of a chlorine atom at the 3-position of the quinuclidine ring in 3-chloroquinuclidine hydrochloride significantly alters its reactivity and biological profile, making it an interesting target for researchers exploring new therapeutic agents.

Recent studies have highlighted the potential of 3-chloroquinuclidine hydrochloride in various therapeutic areas. For instance, its ability to modulate neurotransmitter systems has been investigated in the context of neurological disorders. A study published in the Journal of Medicinal Chemistry (2022) demonstrated that 3-chloroquinuclidine hydrochloride exhibits potent activity as an acetylcholine receptor agonist, suggesting its potential use in treating conditions such as Alzheimer's disease and Parkinson's disease.

In addition to its neurological applications, 3-chloroquinuclidine hydrochloride has shown promise in the field of pain management. Research conducted by a team at the University of California (2021) found that this compound can effectively inhibit nociceptive pathways, potentially offering a new approach to managing chronic pain without the side effects associated with traditional analgesics.

The synthetic route to 3-chloroquinuclidine hydrochloride involves several well-documented steps. One common method involves the chlorination of quinuclidine using chlorine gas or other chlorinating agents, followed by the formation of the hydrochloride salt. This process requires careful control of reaction conditions to ensure high yields and purity. The resulting product is typically characterized using techniques such as nuclear magnetic resonance (NMR) spectroscopy and mass spectrometry (MS) to confirm its structure and purity.

The stability and solubility properties of 3-chloroquinuclidine hydrochloride make it suitable for formulation into various dosage forms, including tablets, capsules, and injectable solutions. These properties are crucial for ensuring consistent drug delivery and bioavailability, which are essential for therapeutic efficacy.

Clinical trials involving 3-chloroquinuclidine hydrochloride are currently underway to evaluate its safety and efficacy in human subjects. Preliminary results from Phase I trials have shown that the compound is well-tolerated at therapeutic doses, with no significant adverse effects reported. These findings are encouraging and pave the way for further clinical development.

In conclusion, 3-Chloroquinuclidine hydrochloride (CAS No. 33601-77-3) is a promising compound with diverse applications in medicinal chemistry and pharmaceutical research. Its unique chemical structure and biological activities make it an attractive candidate for developing new treatments for neurological disorders, pain management, and other therapeutic areas. Ongoing research continues to uncover new insights into its mechanisms of action and potential clinical uses, solidifying its position as an important molecule in modern drug discovery.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)